|
425 Metro Place North, Ste. 300 Dublin, OH 43017-1367 OH Tel. 614-793-7500 Toll Free 800-793-0079 Fax 614-793-7520 |
Type: Public
On the web:
http://www.neoprobe.com
Employees:
25
Employee growth: 19.0%
Neoprobe makes products for the diagnosis and treatment of cancer, such as lymphatic mapping instruments (including the neo2000) that help surgeons identify trends about the spread of cancer in a patient. Subsidiary Cardiosonix markets non-invasive blood flow measurement devices under the Quantix brand. Neoprobe has additional products under development including procedural tracing agent Lymphoseek to be used in lymphatic mapping and handheld radiation probe RIGScan to locate tumors. The company is also working on an activated cellular therapy technology to treat cancers and viral and autoimmune diseases. The procedure activates certain lymph nodes to boost a patient's immune system.
Key numbers for fiscal year ending December, 2008:
Sales: $7.9M
One year growth: 10.7%
Net income: ($5.2)M
Officers:
Chairman: Carl J. Aschinger Jr.
President, CEO, and Director: David C. Bupp
VP Finance, CFO, Treasurer, and Secretary: Brent L. Larson
Competitors:
Biotel
GE Healthcare
SenoRx
